Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the increasing use of low-molecular-weight heparins, including drugs from Sanofi-Aventis, GlaxoSmithKline, and Pfizer, the market dominance of these therapies in the treatment and prophylaxis of venous thromboembolism will be significantly eroded by novel agents over the 2005-2015 forecast period.

The new Pharmacor report Venous Thromboembolism finds that Sanofi-Aventis's Clexane/Lovenox (enoxaparin), GlaxoSmithKline's Fraxiparine (nadroparin), and Pfizer's Fragmin (dalteparin) will increase the overall value of the market owing to their increased use in venous thromboembolism prophylaxis following surgery and a continuing switch from the use of unfractionated heparin. However, new anticoagulants from Bayer, Boehringer Ingelheim, and Sanofi-Aventis will propel novel drug classes to garner 59% of the total market in 2015, severely eroding the dominance of low-molecular-weight heparins.

The report also finds that the withdrawal of AstraZeneca's Exanta (ximelagatran) has created significant opportunity in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom for the development of new oral anticoagulants to treat the disease.

"The critical need for a safe, effective, and predictable oral anticoagulant remains unfulfilled in treating venous thromboembolism," said Mark Thornton, Ph.D., analyst at Decision Resources, Inc. "The high-profile withdrawal of Exanta, the first oral direct thrombin inhibitor to reach the market, has created an opportunity for drug makers that can develop therapies that address the unmet need for a consistently effective oral anticoagulant."

About Venous Thromboembolism

The process known as venous thromboembolism comprises two distinct conditions: deep vein thrombosis and pulmonary embolism. Deep vein thrombosis and pulmonary embolism are major causes of morbidity and mortality in hospitalized patients, with an estimated 20% mortality for pulmonary embolism at six months. These conditions, easily avoided with appropriate prophylaxis, are the most common cause of unexpected death in hospitalized patients.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

New Oral Drugs from Endo Pharmaceuticals and Cephalon Will Drive Sales to More Than $22 Billion in the Acute Pain Market

View Now